- Home
- CRDF vs LUNG Comparison
CRDF vs LUNG Comparison
Compare CRDF & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- LUNG
- Stock Information
- Founded
- CRDF 1999
- LUNG 1995
- Country
- CRDF United States
- LUNG United States
- Employees
- CRDF N/A
- LUNG N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- LUNG Industrial Specialties
- Sector
- CRDF Health Care
- LUNG Health Care
- Exchange
- CRDF Nasdaq
- LUNG Nasdaq
- Market Cap
- CRDF 196.2M
- LUNG N/A
- IPO Year
- CRDF N/A
- LUNG 2020
- Fundamental
- Price
- CRDF $2.63
- LUNG $3.64
- Analyst Decision
- CRDF Strong Buy
- LUNG Strong Buy
- Analyst Count
- CRDF 4
- LUNG 7
- Target Price
- CRDF $12.00
- LUNG $12.07
- AVG Volume (30 Days)
- CRDF 1.1M
- LUNG 416.9K
- Earning Date
- CRDF 05-20-2025
- LUNG 04-30-2025
- Dividend Yield
- CRDF N/A
- LUNG N/A
- EPS Growth
- CRDF N/A
- LUNG N/A
- EPS
- CRDF N/A
- LUNG N/A
- Revenue
- CRDF $683,000.00
- LUNG $87,473,000.00
- Revenue This Year
- CRDF N/A
- LUNG $17.97
- Revenue Next Year
- CRDF N/A
- LUNG $18.88
- P/E Ratio
- CRDF N/A
- LUNG N/A
- Revenue Growth
- CRDF 39.96
- LUNG 19.84
- 52 Week Low
- CRDF $2.01
- LUNG $4.15
- 52 Week High
- CRDF $5.64
- LUNG $10.01
- Technical
- Relative Strength Index (RSI)
- CRDF 41.22
- LUNG 26.86
- Support Level
- CRDF $2.42
- LUNG $3.39
- Resistance Level
- CRDF $2.87
- LUNG $5.46
- Average True Range (ATR)
- CRDF 0.18
- LUNG 0.43
- MACD
- CRDF 0.01
- LUNG -0.06
- Stochastic Oscillator
- CRDF 24.42
- LUNG 12.92
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.